Olaf Wendler (London, UK) talks to BLearning about the highlights from the ‘New Developments in TAVI’ session which took place at EuroPCR 2019 (21–24 May, Paris, France). Despite recently reaching “a high level of TAVI success in terms of outcomes” Wendler notes that it is “nice to see that there is still investment in new technology”.
He discusses the development of TAVI in emerging markets such as India and China, which provides “a little more competition in the market”. This will “hopefully also result in a lower cost for TAVI devices in Europe and North America, which, in the end, will be crucial as the treatment is rolled out to a larger population,” he adds.
Add comment